Company Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 03:41:28 2024-04-15 pm EDT			5-day change	1st Jan Change
0.98 ^USD	-3.92%		-5.76%	-18.32%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Mar. 13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Number of employees: 18

Managers	Title	Age	Since
Sumit Aggarwal CEO	Chief Executive Officer	-	21-03-31
Daniel Geffken DFI	Director of Finance/CFO	67	20-10-31
Ali Hariri CTO	Chief Tech/Sci/R&D Officer	-	21-09-07
Barbara Ryan IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Steven Rubin BRD	Director/Board Member	63	14-04-30
Alan Walts BRD	Director/Board Member	64	21-03-31
Sumit Aggarwal CEO	Chief Executive Officer	-	21-03-31
Lindsay Androski BRD	Director/Board Member	-	22-07-04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,143,390	3,006,085 ( 95.63 %)	0	95.63 %

Name	Equities	%	Valuation
Pontifax Management Co. Ltd. 11.65 %	366,225	11.65 %	366 225 $
Gurnet Point Capital LLC 3.958 %	124,417	3.958 %	124 417 $
MENORA MIVTACHIM HOLDINGS LTD 1.666 %	52,355	1.666 %	52 355 $
Altshuler Shaham Investments House Ltd. 0.7992 %	25,123	0.7992 %	25 123 $
CLAL INSURANCE ENTERPRISES HOLDINGS LTD. 0.4303 %	13,526	0.4303 %	13 526 $
Sumit Aggarwal 0.1568 %	4,930	0.1568 %	4 930 $
Vijay Modur 0.1232 %	3,873	0.1232 %	3 873 $
ROCHE HOLDING AG 0.0602 %	1,893	0.0602 %	1 893 $
Daniel Geffken 0.0398 %	1,250	0.0398 %	1 250 $
Alan Walts 0.0300 %	942	0.0300 %	942 $

Eloxx Pharmaceuticals, Inc.

480 Arsenal Way Suite 130

02451, Watertown

http://www.eloxxpharma.com

address Eloxx Pharmaceuticals, Inc.(ELOX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.98 USD

Average target price

30 USD

Spread / Average Target

+2,961.07%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ELOXX PHARMACEUTICALS, INC.	-18.32%	3.23M
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	103B
REGENERON PHARMACEUTICALS, INC.	+2.31%	96.56B
ARGENX SE	+4.22%	22.61B
BIONTECH SE	-16.72%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-23.26%	14.46B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.25B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.1B

Bio Therapeutic Drugs